Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

FMI’s latest analysis underscores a remarkable surge in demand for pharmaceutical products within the Kingdom, with market value expected to exceed USD 10,113.1 million by 2024. This impressive growth ...

General Anesthesia Drugs MarketThe global general anesthesia drugs market, valued at USD 4,978.1 million in 2023, is poised for steady growth, with projections indicating a compound annual growth rate ...

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

The UK pharma company says it has now withdrawn ... propionate/salmeterol) partnered with Hikma, and other inhaled and non-inhaled products that generate royalty streams. It also gets royalties ...

Novartis’ Sandoz generics arm, and Hikma have tried unsuccessfully ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and ...

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...